Meiji Seika Pharma Co., Ltd. (headquartered in Tokyo; President and Representative Director: Toshiaki Nagasato) today announced that the results of the Integral-1 study, one of tw ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results